{"organizations": [], "uuid": "a1c0e457085a3383d8e1a3143e397b230f172ffd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abbvie-gets-positive-recommendatio/brief-abbvie-gets-positive-recommendation-from-pan-canadian-oncology-drug-review-for-venclexta-idUSFWN1QO0DR", "country": "US", "domain_rank": 408, "title": "BRIEF-AbbVie Gets Positive Recommendation From Pan-Canadian Oncology Drug Review For Venclexta", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.984, "site_type": "news", "published": "2018-03-06T21:33:00.000+02:00", "replies_count": 0, "uuid": "a1c0e457085a3383d8e1a3143e397b230f172ffd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abbvie-gets-positive-recommendatio/brief-abbvie-gets-positive-recommendation-from-pan-canadian-oncology-drug-review-for-venclexta-idUSFWN1QO0DR", "ord_in_thread": 0, "title": "BRIEF-AbbVie Gets Positive Recommendation From Pan-Canadian Oncology Drug Review For Venclexta", "locations": [], "entities": {"persons": [{"name": "pcodr", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - AbbVie Inc:\n* ABBVIE RECEIVES POSITIVE RECOMMENDATION FROM THE PAN-CANADIAN ONCOLOGY DRUG REVIEW FOR VENCLEXTA™ - AN ORAL THERAPY FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)\n* ABBVIE CANADA - PCODR CONDITIONALLY RECOMMENDS REIMBURSEMENT OF VENCLEXTA FOR CLL PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY & FAILED A BCRI​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T21:33:00.000+02:00", "crawled": "2018-03-07T19:34:10.000+02:00", "highlightTitle": ""}